• linkedin
  • Increase Font
  • Sharebar

    Atopic dermatitis: Biologics to watch in 2018


    Targeting IL-13

    Tralokinumab and lebrikizumab are IL-13 specific monoclonal antibodies originally were developed for treating asthma and other inflammatory conditions. Both drugs have completed phase 2 trials in AD patients.

    “The results of both studies suggest that further study of anti- IL-13 therapies in AD are warranted, and they have the potential to provide a valuable treatment option in the future,” Patel and Strowd wrote in their review.

    Results of the tralokinumab study showed that patients in the highest two dose groups had significant improvement in baseline EASI score vs placebo, as well as significant improvements in the Dermatology Life Quality Index (DLQI) according to the authors.

    Likewise, in the randomized phase 2 study of lebrikizumab, which included 209 adults with moderate-to-severe AD who had failed topical corticosteroids, patients randomized to monthly dosing of lebrikizumab had EASI 50 and EASI 75 response rates that were significantly better than placebo and continued to improve over the course of the 12 week trial, according to Patel and Strowd.

    NEXT: Targeting IL-31



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow